Albireo Pharma - ALBO Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Albireo Pharma in the last twelve months. There are currently 6 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALBO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALBO, but not buy additional shares or sell existing shares.
View ALBO analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued 12-month price objectives for Albireo Pharma's stock. Their ALBO share price forecasts range from $42.00 to $59.00. On average, they predict the company's stock price to reach $48.00 in the next year. This suggests a possible upside of 7.6% from the stock's current price.
View analysts price targets for ALBO or view top-rated stocks among Wall Street analysts.

Albireo Pharma's stock was trading at $21.61 on January 1st, 2023. Since then, ALBO shares have increased by 106.3% and is now trading at $44.59.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our ALBO earnings forecast.

Albireo Pharma, Inc. (NASDAQ:ALBO) issued its quarterly earnings results on Thursday, November, 4th. The biopharmaceutical company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $3.28. The biopharmaceutical company earned $3.66 million during the quarter, compared to analysts' expectations of $22.33 million. Albireo Pharma had a negative net margin of 228.51% and a negative trailing twelve-month return on equity of 97.13%. During the same period last year, the company earned ($1.96) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Albireo Pharma investors own include Energy Transfer (ET), Heat Biologics (HTBX), Amarin (AMRN), Exelixis (EXEL), Palatin Technologies (PTN), GW Pharmaceuticals (GWPH), Viking Therapeutics (VKTX), Agenus (AGEN), OPKO Health (OPK) and Pfizer (PFE).

Albireo Pharma trades on the NASDAQ under the ticker symbol "ALBO."

Albireo Pharma's stock is owned by a number of retail and institutional investors. Top institutional investors include Chicago Capital LLC (6.58%), Rice Hall James & Associates LLC (2.48%), International Biotechnology Trust PLC (0.18%), Simplex Trading LLC (0.00%), Zurcher Kantonalbank Zurich Cantonalbank (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Jan Mattsson, Jason Duncan, Life Sciences Maste Perceptive, Martha J Carter, Pamela Stephenson, Patrick Taylor Horn, Perceptive Advisors Llc, Ronald Harold Wilfred Cooper and Simon NR Harford.
View institutional ownership trends.

Shares of ALBO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALBO stock can currently be purchased for approximately $44.59.

Albireo Pharma (NASDAQ:ALBO) has a market capitalization of $923.01 million and generates $40.58 million in revenue each year. The biopharmaceutical company earns $-34,030,000.00 in net income (profit) each year or ($6.72) on an earnings per share basis.

The company employs 130 workers across the globe.

Albireo Pharma's mailing address is 10 POST OFFICE SQUARE SUITE 502 SOUTH, BOSTON MA, 02109. The official website for the company is www.albireopharma.com. The biopharmaceutical company can be reached via phone at (857) 254-5555, via email at shareholders@biodel.com, or via fax at 203-796-5001.